Axis-Shield buys Nycomed Diagnostics for $35 million
This article was originally published in Clinica
Executive Summary
Axis-Shield, the UK company which has been building a cardiac diagnostics franchise with its homocysteine and activated factor XII (AFT) tests, is diversifying by buying the diagnostics business of Nycomed Pharma, for £22 million ($35 million).